Ventyx Biosciences, Inc.

NASDAQ•VTYX

CEO: Dr. Sheila K. Gujrathi M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-10-21

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Contact Information

12790 El Camino Real, Suite 200, San Diego, CA, 92130, United States

760-593-4832

ventyxbio.com

Market Cap

$1.00B

P/E (TTM)

-9.4

17.5

Dividend Yield

52W High

$25.00

52W Low

$0.78

52W Range

55%

Rank59Top 87.6%

2.2

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.32-36.00%

4-Quarter Trend

FCF

-$17.56M-50.49%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Nine-month net loss narrowed to $77.3M USD, improving from $105.8M USD loss last period, reflecting better operational control.

R&D Spending Decreased Total R&D expenses for nine months fell $29.3M USD to $62.9M USD, primarily due to closeout of older development programs.

Operating Cash Burn Improved Cash used in operating activities decreased to $64.5M USD over nine months, showing better cash management compared to prior year.

VTX3232 Clinical Data Positive Reported positive topline results for VTX3232 in early-stage Parkinson's Phase 2a trial in June 2025 and obesity trial in October 2025.

Risk Factors

Future Financing Requirements High Substantial additional capital needed for development; failure to secure funding could delay or terminate critical product development efforts.

Clinical Trial Data Uncertainty Preliminary data may change materially upon audit; high attrition rate in clinical development remains a significant inherent risk factor.

VTX958 Internal Resource Reduction Will not commit significant internal resources to VTX958 development following Crohn's Phase 2 results, refining future strategy.

Stock Price Volatility Expected Stock price highly volatile based on clinical trial announcements and general market conditions; potential for significant investor loss.

Outlook

VTX2735 Phase 2 Results Due Anticipate interim topline results for VTX2735 Phase 2 trial in recurrent pericarditis during the fourth quarter of 2025.

Tamuzimod Partnering Exploration Intend to identify a partner or secure non-dilutive financing to support the pivotal Phase 3 program for tamuzimod in UC.

Cash Sufficient Twelve Months Current cash, equivalents, and marketable securities estimated sufficient to fund obligations for at least twelve months from report date.

Continue IP Protection Efforts Will continue efforts to obtain and enforce patent protection for product candidates against potential third-party infringement and maintain competitive edge.

Peer Comparison

Revenue (TTM)

RIGL

$294.28M

+64.1%

RGNX

$170.44M

+104.5%

GOSS

$44.05M

-58.2%

Gross Margin (Latest Quarter)

GOSS

100.0%

+0.0pp

ABSI

100.0%

+197.2pp

VYGR

93.2%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CRVS	$1.34B	-82.7	-23.3%	1.3%
MLTX	$1.22B	-4.8	-67.1%	17.8%
OLMA	$1.17B	-8.5	-41.5%	1.3%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data